Drugs / EB-DUALNK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07589543 | Mar 2026 → Mar 2027 expected | malignant epithelial tumor of ovary | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DUALNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589543 ↗ |
| Modality | Cell therapy | “dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy” NCT07589543 ↗ |
| Route | Other | “single infusion of EB-DUALNK” NCT07589543 ↗ |